-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $13,840.00 in Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $13,840.00 in Stock
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 1,000 shares of the firm's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $13.84 per share, with a total value of $13,840.00. Following the completion of the purchase, the chief executive officer now owns 2,722,886 shares of the company's stock, valued at approximately $37,684,742.24. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Snehal Patel also recently made the following trade(s):
Get Greenwich LifeSciences alerts:- On Wednesday, November 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.79 per share, with a total value of $17,580.00.
- On Friday, October 14th, Snehal Patel purchased 3,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.75 per share, with a total value of $29,250.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Thursday, September 29th, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.23 per share, with a total value of $9,230.00.
Greenwich LifeSciences Stock Performance
Shares of NASDAQ:GLSI opened at $13.70 on Friday. Greenwich LifeSciences, Inc. has a 52-week low of $6.82 and a 52-week high of $36.00. The business has a 50-day moving average price of $10.71 and a 200-day moving average price of $9.55.
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Analysts forecast that Greenwich LifeSciences, Inc. will post -0.57 EPS for the current year.Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of GLSI. Pura Vida Investments LLC acquired a new stake in Greenwich LifeSciences during the third quarter worth about $179,000. Walleye Capital LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $90,000. Goldman Sachs Group Inc. acquired a new stake in Greenwich LifeSciences during the second quarter worth about $104,000. Occudo Quantitative Strategies LP acquired a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $130,000. 8.06% of the stock is currently owned by hedge funds and other institutional investors.
About Greenwich LifeSciences
(Get Rating)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Read More
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel purchased 1,000 shares of the firm's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $13.84 per share, with a total value of $13,840.00. Following the completion of the purchase, the chief executive officer now owns 2,722,886 shares of the company's stock, valued at approximately $37,684,742.24. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
格林威治生命科学公司(纳斯达克代码:GET Rating)首席执行官斯内哈尔·帕特尔在12月2日星期五的一笔交易中购买了该公司1,000股股票。该股的收购均价为每股13.84美元,总价值为13,840.00美元。收购完成后,首席执行官现在拥有2,722,886股公司股票,价值约37,684,742.24美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站.
Snehal Patel also recently made the following trade(s):
斯内哈尔·帕特尔最近还进行了以下交易:
- On Wednesday, November 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.79 per share, with a total value of $17,580.00.
- On Friday, October 14th, Snehal Patel purchased 3,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $9.75 per share, with a total value of $29,250.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Friday, October 7th, Snehal Patel acquired 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.72 per share, with a total value of $19,440.00.
- On Thursday, September 29th, Snehal Patel acquired 1,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.23 per share, with a total value of $9,230.00.
- 11月2日星期三,斯内哈尔·帕特尔购买了2,000股格林威治生命科学公司的股票。该股是以每股8.79美元的平均价格收购的,总价值为17,580.00美元。
- 10月14日,星期五,斯内哈尔·帕特尔购买了3,000股格林威治生命科学公司的股票。该股是以每股9.75美元的平均价格收购的,总价值为29,250.00美元。
- 10月7日,星期五,斯内哈尔·帕特尔收购了格林威治生命科学公司的2000股股票。这只股票是以每股9.72美元的平均价格购买的,总价值为19,440.00美元。
- 10月7日,星期五,斯内哈尔·帕特尔收购了格林威治生命科学公司的2000股股票。这只股票是以每股9.72美元的平均价格购买的,总价值为19,440.00美元。
- 9月29日,星期四,Snehal Patel收购了1,000股Greenwich LifeSciences股票。该股是以每股9.23美元的平均价格购买的,总价值为9,230.00美元。
Greenwich LifeSciences Stock Performance
格林威治生命科学公司股票表现
Shares of NASDAQ:GLSI opened at $13.70 on Friday. Greenwich LifeSciences, Inc. has a 52-week low of $6.82 and a 52-week high of $36.00. The business has a 50-day moving average price of $10.71 and a 200-day moving average price of $9.55.
纳斯达克:GLSI上周五开盘报13.7美元。Greenwich LifeSciences,Inc.的股价为6.82美元,为52周低点,52周高点为36.00美元。该业务的50日移动均线价格为10.71美元,200日移动均线价格为9.55美元。
Institutional Inflows and Outflows
机构资金流入和流出
Several institutional investors have recently modified their holdings of GLSI. Pura Vida Investments LLC acquired a new stake in Greenwich LifeSciences during the third quarter worth about $179,000. Walleye Capital LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $90,000. Goldman Sachs Group Inc. acquired a new stake in Greenwich LifeSciences during the second quarter worth about $104,000. Occudo Quantitative Strategies LP acquired a new stake in Greenwich LifeSciences during the second quarter worth about $199,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Greenwich LifeSciences during the second quarter worth about $130,000. 8.06% of the stock is currently owned by hedge funds and other institutional investors.
几家机构投资者最近调整了对GLSI的持股。Pura Vida Investments LLC在第三季度收购了Greenwich LifeSciences的新股份,价值约17.9万美元。Walleye Capital LLC在第二季度收购了Greenwich LifeSciences价值约9万美元的新股份。高盛股份有限公司在第二季度收购了格林威治生命科学公司价值约10.4万美元的新股份。Occudo Quantity Strategy LP在第二季度收购了Greenwich LifeSciences的新股份,价值约19.9万美元。最后,立体主义系统战略有限责任公司在第二季度收购了格林威治生命科学公司价值约13万美元的新股份。8.06%的股票目前由对冲基金和其他机构投资者持有。
About Greenwich LifeSciences
关于格林威治生命科学
(Get Rating)
(获取评级)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
格林威治生命科学公司是一家临床阶段的生物制药公司,专注于为乳腺癌和其他表达HER2/neu的癌症开发新型癌症免疫疗法。它的主要候选产品是GP2,这是一种免疫疗法,已经完成了IIb期临床试验,以防止以前接受过手术的患者的乳腺癌复发。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- 免费获取StockNews.com关于格林威治生命科学(GLSI)的研究报告
- 辉瑞、强生能否继续跑赢该指数?
- 这就是为什么达科电子在一天内下跌了40%
- 是时候在Gamestop上认输了吗?
- 为什么你应该避免Carvana,即使它可以避免破产
- 投资者是否听到了Spotify下跌趋势的终结?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《格林威治生活科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Greenwich LifeSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧